216 related articles for article (PubMed ID: 27497757)
1. Precision medicine in acute myeloid leukemia: Hope, hype or both?
Prasad V; Gale RP
Leuk Res; 2016 Sep; 48():73-7. PubMed ID: 27497757
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M; Pettersson L
APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
[TBL] [Abstract][Full Text] [Related]
3. [Precision medicine for acute myeloid leukemia based on genomic profiling].
Sanada M
Rinsho Ketsueki; 2019; 60(7):847-853. PubMed ID: 31391376
[TBL] [Abstract][Full Text] [Related]
4. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
6. Precision Medicine in Myeloid Malignancies: Hype or Hope?
Upadhyay Banskota S; Khanal N; Marar RI; Dhakal P; Bhatt VR
Curr Hematol Malig Rep; 2022 Dec; 17(6):217-227. PubMed ID: 35972641
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine for acute myeloid leukemia.
Lai C; Karp JE; Hourigan CS
Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
[TBL] [Abstract][Full Text] [Related]
8. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Heuser M; Mina A; Stein EM; Altman JK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
10. Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.
Reville PK; Kadia T
Curr Treat Options Oncol; 2020 Apr; 21(4):34. PubMed ID: 32318829
[TBL] [Abstract][Full Text] [Related]
11. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
Freeman SD; Jovanovic JV; Grimwade D
Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
[TBL] [Abstract][Full Text] [Related]
12. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
13. MRD in AML: it is time to change the definition of remission.
Ossenkoppele GJ; Schuurhuis GJ
Best Pract Res Clin Haematol; 2014; 27(3-4):265-71. PubMed ID: 25455276
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
15. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
Bret C; Viziteu E; Kassambara A; Moreaux J
Expert Rev Hematol; 2016; 9(4):351-60. PubMed ID: 26761438
[TBL] [Abstract][Full Text] [Related]
16. Detection of minimal residual disease in acute myelogenous leukemia.
Raanani P; Ben-Bassat I
Acta Haematol; 2004; 112(1-2):40-54. PubMed ID: 15179004
[TBL] [Abstract][Full Text] [Related]
17. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
Ravandi F; Jorgensen JL
J Natl Compr Canc Netw; 2012 Aug; 10(8):1029-36. PubMed ID: 22878826
[TBL] [Abstract][Full Text] [Related]
18. [Frontline treatment of AML in adults].
Miyamoto T; Kikushige Y; Yoshimoto AG
Rinsho Ketsueki; 2017; 58(10):1884-1894. PubMed ID: 28978829
[TBL] [Abstract][Full Text] [Related]
19. Are we ready for precision medicine in acute myeloid leukemia?
Roboz GJ
Clin Adv Hematol Oncol; 2016 Aug; 14(8):582-4. PubMed ID: 27487100
[No Abstract] [Full Text] [Related]
20. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]